BURLINGTON, NC — LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE® portfolio. The new Certolizumab Concentration and Anti-Certolizumab Antibody DoseASSURETM CTZ assay, helps physicians monitor individual drug response for patients who are on Certolizumab, a biologic drug used to treat certaininflammatory diseases, such as rheumatoid arthritis and Crohn’s disease.
Biologic drugs are complex, protein-based therapies that can be used to treat certain inflammatory diseases and are among the fastest growing class of drugs available today. However, the expense of these medications and the variability in patient response can present numerous challenges. LabCorp’s DoseASSURE® portfolio helps address these challenges by providing quantitative,patient-specific measurement which can guide patienttherapy. With the launch of the DoseASSURE CTZ, LabCorp now has the most comprehensive biologics TDM menu in the industry, targeting the largest number of biologic drugs.
“Biologic drugs can be life-changing, but individual patient response to biologics can vary greatly,” said David P. King, LabCorp’s chairman and CEO. “LabCorp’s DoseASSURE portfolio helps to deliver on the promise of precision medicine by enabling more effective and more individualized treatment plans that can improve clinical outcomes at reduced costs.”
Studies demonstrate the use of TDM can improveefficacy and prolong successful response to biologictreatment. Accordingly, appropriate use of TDM can diminish the need for disease-related surgery and hospitalization by reducing the risk of treatment failure.
“Our expanding DoseASSURE portfolio demonstrates our commitment to providing world-class diagnostic and patient management solutions for physicians and patients,” said Marcia Eisenberg,Ph.D., chief scientific officer of LabCorp Diagnostics.“LabCorp adds value because our diagnostics expertise and available clinical decision support tools help clinicians integrate biologic drugs and the associated diagnostics into optimal patient care.”
DoseASSURE® TDM Portfolio
LabCorp’s TDM DoseASSURE portfolio includes eight assays measuring 10 biologic therapies —including Adalimumab, Infliximab, Infliximab-dyyb, Infliximab-abda, Etanercept, Rituximab, Golimumab,Vedolizumab, Ustekinumab, and Certolizumab.
- Adalimumab and Anti-Adalimumab Antibody, DoseASSURE ADL
- Certolizumab and Anti-Certolizumab Antibody, DoseASSURE CTZ
- Etanercept and Anti-EtanerceptAntibody, Dose ASSURE ETN
- Golimumab and Anti-Golimumab Antibody,DoseASSURE GOL
- Infliximab and Anti-Infliximab Antibody,DoseASSURE IFX
- Rituximab and Anti-Rituximab Antibody,DoseASSURE RTX
- Ustekinumab and Anti-Ustekinumab Antibody,DoseASSURE UST
- Vedolizumab and Anti-Vedolizumab Antibody,DoseASSURE VDZ
For more information about LabCorp’s DoseASSURE portfolio, please visit the online test menu at LabCorp’s website
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenues of more than $11 billion in 2018. To learn more about LabCorp, visit: LabCorp’s website